<p>Nuveen LLC 在第一季度收购了强生（NYSE:JNJ - 免费报告）股票的新头寸，根据其最近向证券交易委员会（SEC）提交的文件。这家机构投资者收购了 8,256,079 股该公司的股票，估值约为 13,691,880,000 美元。Nuveen LLC 在最近的报告期末持有强生约 0.34% 的股份。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>3 大高分红股票，强劲盈利支撑</li>
</ul>
<p>其他几家机构投资者最近也增加或减少了在该公司的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在强生的持股提高了 0.5%。先锋集团目前持有 233,962,679 股该公司的股票，估值为 38,800,371,000 美元，在上个季度又购买了 1,170,120 股。北方信托公司（Northern Trust Corp）在第四季度将其在强生的持股提高了 12.3%。北方信托公司目前持有 30,813,175 股该公司的股票，价值 4,456,201,000 美元，在上个季度又购买了 3,363,235 股。纽约梅隆银行（Bank of New York Mellon Corp）在第一季度将其在强生的持股增加了 26.4%。纽约梅隆银行目前持有 23,182,464 股该公司的股票，价值 3,844,580,000 美元，在此期间又购买了 4,842,582 股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在强生的持股增加了 3.9%。查尔斯·施瓦布投资管理公司目前持有 18,899,263 股该公司的股票，估值为 3,133,602,000 美元，在此期间又购买了 712,181 股。最后，马萨诸塞金融服务公司（Massachusetts Financial Services Co. MA）在第一季度将其在强生的持股增加了 2.5%。马萨诸塞金融服务公司目前持有 18,282,410 股该公司的股票，估值为 3,031,955,000 美元，在此期间又购买了 448,666 股。69.55% 的股票由机构投资者持有。</p>
<h2>强生股票表现</h2>
<p>强生（NYSE JNJ）周五开盘价为 173.40 美元。强生的 1 年最低价为 140.68 美元，1 年最高价为 173.96 美元。该公司的 50 日简单移动平均线为 159.26 美元，200 日简单移动平均线为 157.52 美元。公司的流动比率为 1.01，速动比率为 0.76，债务与股本比率为 0.50。该公司的市值为 4176.1 亿美元，市盈率为 18.55，市盈增长比率为 2.21，贝塔值为 0.41。</p>
<ul>
<li>担心反弹消退？考虑这 3 只分红股票</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）最近于 7 月 16 日（星期三）公布了季度财报。公司报告每股收益（EPS）为 2.77 美元，超出市场共识预期的 2.68 美元，超出 0.09 美元。强生的净利润率为 25.00%，股本回报率为 32.49%。公司本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。去年同期，公司每股收益为 2.82 美元。公司的收入同比增长了 5.8%。整体来看，研究分析师预计强生在当前财政年度的每股收益将达到 10.58 美元。</p>
<h2>强生宣布分红</h2>
<p>该公司最近还宣布了季度分红，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股东将获得每股 1.30 美元的分红。这相当于每年 5.20 美元的分红，分红收益率为 3.0%。除息日为 8 月 26 日（星期二）。强生的派息比率为 55.61%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>4 大主要股票上调 2025 年指引，分析师目标上升</li>
</ul>
<p>一些分析师最近对该公司发布了报告。巴克莱（Barclays）将强生的目标价从 165.00 美元上调至 176.00 美元，并在 7 月 17 日的研究报告中给予该股票 “持平” 评级。雷蒙德·詹姆斯金融（Raymond James Financial）将强生的目标价从 165.00 美元下调至 162.00 美元，并在 4 月 14 日的研究报告中对该股票给予 “跑赢大盘” 评级。Leerink Partners 将强生的评级从 “跑赢大盘” 下调至 “市场表现”，并在 5 月 13 日的研究报告中将该股票的目标价从 169.00 美元下调至 153.00 美元。派珀·桑德勒（Piper Sandler）在 7 月 17 日的研究报告中重申了对强生股票的 “增持” 评级。最后，美国银行（Bank of America）将强生股票的目标价从 161.00 美元上调至 175.00 美元，并在 7 月 17 日的报告中给予该股票 “中性” 评级。九位股票研究分析师对该股票给予了持有评级，十位给予了买入评级，两位给予了强烈买入评级。根据 MarketBeat.com 的数据，强生目前的共识评级为 “适度买入”，共识目标价为 174.50 美元。</p>
<p><strong>阅读我们对 JNJ 的最新分析</strong></p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗科技两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>消费者物价指数测量什么？</li>
<li>火箭实验室报告第二季度业绩：牛市论点是否依然成立？</li>
<li>基础材料股票投资</li>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>现在是购买 Cheniere Energy 的好时机：预计将创下新高</li>
</ul>
<p><strong>想知道其他对冲基金持有的强生股票吗？</strong> 请访问 HoldingsChannel.com 获取强生（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Nuveen LLC 在第一季度收购了强生（NYSE: JNJ）的新股份，购买了 8,256,079 股，价值约为 13.7 亿美元。这次收购使 Nuveen 的持股比例达到公司总股份的约 0.34%。其他机构投资者，包括先锋集团和北方信托，也增加了在强生的持股。该股票目前的交易价格为 173.40 美元，市值为 4176.1 亿美元，股息收益率为 3.0%</p>

<p>Nuveen LLC acquired a new position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,256,079 shares of the company's stock, valued at approximately $1,369,188,000. Nuveen LLC owned approximately 0.34% of Johnson &amp; Johnson at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Nuveen LLC 在第一季度收购了强生（NYSE:JNJ - 免费报告）股票的新头寸，根据其最近向证券交易委员会（SEC）提交的文件。这家机构投资者收购了 8,256,079 股该公司的股票，估值约为 13,691,880,000 美元。Nuveen LLC 在最近的报告期末持有强生约 0.34% 的股份。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 大高分红股票，强劲盈利支撑</li>
</ul>
</div><p>Several other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Johnson &amp; Johnson by 0.5% in the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock valued at $38,800,371,000 after buying an additional 1,170,120 shares during the last quarter. Northern Trust Corp boosted its position in shares of Johnson &amp; Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Johnson &amp; Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Johnson &amp; Johnson by 3.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock valued at $3,133,602,000 after purchasing an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Johnson &amp; Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock valued at $3,031,955,000 after buying an additional 448,666 shares during the period. 69.55% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也增加或减少了在该公司的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在强生的持股提高了 0.5%。先锋集团目前持有 233,962,679 股该公司的股票，估值为 38,800,371,000 美元，在上个季度又购买了 1,170,120 股。北方信托公司（Northern Trust Corp）在第四季度将其在强生的持股提高了 12.3%。北方信托公司目前持有 30,813,175 股该公司的股票，价值 4,456,201,000 美元，在上个季度又购买了 3,363,235 股。纽约梅隆银行（Bank of New York Mellon Corp）在第一季度将其在强生的持股增加了 26.4%。纽约梅隆银行目前持有 23,182,464 股该公司的股票，价值 3,844,580,000 美元，在此期间又购买了 4,842,582 股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在强生的持股增加了 3.9%。查尔斯·施瓦布投资管理公司目前持有 18,899,263 股该公司的股票，估值为 3,133,602,000 美元，在此期间又购买了 712,181 股。最后，马萨诸塞金融服务公司（Massachusetts Financial Services Co. MA）在第一季度将其在强生的持股增加了 2.5%。马萨诸塞金融服务公司目前持有 18,282,410 股该公司的股票，估值为 3,031,955,000 美元，在此期间又购买了 448,666 股。69.55% 的股票由机构投资者持有。</p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>强生股票表现</h2>
</div><p>NYSE JNJ opened at $173.40 on Friday. Johnson &amp; Johnson has a 1 year low of $140.68 and a 1 year high of $173.96. The firm's 50 day simple moving average is $159.26 and its 200 day simple moving average is $157.52. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $417.61 billion, a price-to-earnings ratio of 18.55, a P/E/G ratio of 2.21 and a beta of 0.41.</p>
<div class="lb-trans"><p>强生（NYSE JNJ）周五开盘价为 173.40 美元。强生的 1 年最低价为 140.68 美元，1 年最高价为 173.96 美元。该公司的 50 日简单移动平均线为 159.26 美元，200 日简单移动平均线为 157.52 美元。公司的流动比率为 1.01，速动比率为 0.76，债务与股本比率为 0.50。该公司的市值为 4176.1 亿美元，市盈率为 18.55，市盈增长比率为 2.21，贝塔值为 0.41。</p>
</div><ul>
<li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>担心反弹消退？考虑这 3 只分红股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the firm posted $2.82 EPS. The firm's revenue was up 5.8% on a year-over-year basis. As a group, research analysts expect that Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近于 7 月 16 日（星期三）公布了季度财报。公司报告每股收益（EPS）为 2.77 美元，超出市场共识预期的 2.68 美元，超出 0.09 美元。强生的净利润率为 25.00%，股本回报率为 32.49%。公司本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。去年同期，公司每股收益为 2.82 美元。公司的收入同比增长了 5.8%。整体来看，研究分析师预计强生在当前财政年度的每股收益将达到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生宣布分红</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson &amp; Johnson's payout ratio is 55.61%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股东将获得每股 1.30 美元的分红。这相当于每年 5.20 美元的分红，分红收益率为 3.0%。除息日为 8 月 26 日（星期二）。强生的派息比率为 55.61%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise</li>
</ul>
<div class="lb-trans"><ul>
<li>4 大主要股票上调 2025 年指引，分析师目标上升</li>
</ul>
</div><p>A number of analysts recently issued reports on the company. Barclays increased their target price on Johnson &amp; Johnson from $165.00 to $176.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Raymond James Financial lowered their target price on Johnson &amp; Johnson from $165.00 to $162.00 and set an &#34;outperform&#34; rating on the stock in a research report on Monday, April 14th. Leerink Partners lowered shares of Johnson &amp; Johnson from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and dropped their price target for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Piper Sandler reaffirmed an &#34;overweight&#34; rating on shares of Johnson &amp; Johnson in a research report on Thursday, July 17th. Finally, Bank of America lifted their target price on shares of Johnson &amp; Johnson from $161.00 to $175.00 and gave the stock a &#34;neutral&#34; rating in a report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson &amp; Johnson currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $174.50.</p>
<div class="lb-trans"><p>一些分析师最近对该公司发布了报告。巴克莱（Barclays）将强生的目标价从 165.00 美元上调至 176.00 美元，并在 7 月 17 日的研究报告中给予该股票 “持平” 评级。雷蒙德·詹姆斯金融（Raymond James Financial）将强生的目标价从 165.00 美元下调至 162.00 美元，并在 4 月 14 日的研究报告中对该股票给予 “跑赢大盘” 评级。Leerink Partners 将强生的评级从 “跑赢大盘” 下调至 “市场表现”，并在 5 月 13 日的研究报告中将该股票的目标价从 169.00 美元下调至 153.00 美元。派珀·桑德勒（Piper Sandler）在 7 月 17 日的研究报告中重申了对强生股票的 “增持” 评级。最后，美国银行（Bank of America）将强生股票的目标价从 161.00 美元上调至 175.00 美元，并在 7 月 17 日的报告中给予该股票 “中性” 评级。九位股票研究分析师对该股票给予了持有评级，十位给予了买入评级，两位给予了强烈买入评级。根据 MarketBeat.com 的数据，强生目前的共识评级为 “适度买入”，共识目标价为 174.50 美元。</p>
</div><p><strong>Read Our Latest Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 JNJ 的最新分析</strong></p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗科技两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What does consumer price index measure?</li>
<li>Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?</li>
<li>Basic Materials Stocks Investing</li>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>Now Is a Great Time to Buy Cheniere Energy: New High Expected</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>消费者物价指数测量什么？</li>
<li>火箭实验室报告第二季度业绩：牛市论点是否依然成立？</li>
<li>基础材料股票投资</li>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>现在是购买 Cheniere Energy 的好时机：预计将创下新高</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对冲基金持有的强生股票吗？</strong> 请访问 HoldingsChannel.com 获取强生（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Nuveen LLC 购入了强生公司（NYSE: JNJ）的新股份